Biotech

BRUNCH

Forget chasing the next Pfizer: Singapore’s biotech future lies in innovation, not giants

The Republic may not have a major player to call its own, but licensing deals and early-stage breakthroughs can still count as wins

Six of this year's Emerging Enterprise finalists show how technology can transform the way we live, work and stay healthy.
EMERGING ENTERPRISE AWARDS 2025

Redefining industries through innovation and insight

These Emerging Enterprise Awards finalists are applying technology and data to make businesses more efficient and improve lives

Novartis, which focuses on heart, kidney and metabolic drugs, immunology, neuroscience and oncology, is looking to boost its portfolio.

Novartis agrees to buy Avidity in US$12 billion biotech deal

The full deal is expected to close in the first half of 2026, subject to the completion of the separation

Dr Roland Ong, founder and chairman of Nanyang Biologics,  says: “Biotech, AI and drug discovery are a long-term R&D process and continuous funding is required.”

Singapore biotech startup Nanyang Biologics bets on AI drug discovery platform to unlock revenue

After investing six years in R&D, the firm is heading to Nasdaq via a US$1.5 billion Spac deal as it lands its first client

Compared with other industries, biotech startups typically have long and uncertain timelines, as well as high capital requirements – all of which translate into perceived higher risk.

Challenging economic conditions raise the bar for nascent biotech startups as funding dries up

The pullback in science and tech funding in the US has cooled investor sentiment for now, but observers say more money may eventually flow into Asia and Europe

The impact of Trump’s pharma tariffs on drugmakers is evident, but the upstream implications for startups developing novel drugs are less clear.

Singapore draws international biotech VCs as Asia-Pacific life sciences sector takes off

Trump’s tariffs may prompt firms to reassess investments, but the sector’s long-term outlook is unlikely to change

China has accounted for over 75% of regional venture capital and private equity funding since 2019, and now contributes 26.7% of all drugs in the global development pipeline – up from 23.6% the year before, says Bain & Company.

China’s biotech boom: Collaboration, not competition, for Singapore

While China dominates global drug development, Singapore’s strength lies in bridging Asian innovation with Western capital, say industry players

Less-than-favourable valuations for biopharma companies may be a key reason behind the lack of such companies listing on the SGX.

The biopharma scene in Singapore is vibrant, but few make it to SGX

More listings will keep the Republic’s capital markets robust, develop an ecosystem and strengthen its regional hub status 

There have been 17 new Hong Kong equity ETFs launched in China this year, with another 16 applications in the pipeline submitted to the securities watchdog.

Hong Kong stock ETFs get record China money on AI, biotech craze

Mainland retail traders are being lured by the outperformance of the city’s equities, combined with their accessibility and abundance of new products to choose from

The Hong Kong-listed company did not declare any dividend for the six-month period.

A*Star biotech spin-off Mirxes trims losses to US$28.4 million as top line grows

Higher revenue is driven by increased contributions from its early detection and precision multi-omics segment